Biologics and Biosimilars Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology  

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Biologics and Biosimilars Market 

5.1. COVID-19 Landscape: Biologics and Biosimilars Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Biologics and Biosimilars Market, By Product Category

8.1. Biologics and Biosimilars Market Revenue and Volume, by Product Category

8.1.1. Monoclonal antibodies 

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Vaccines 

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Recombinant hormones 

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Cytokines and interferons 

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Blood factors 

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Other biologics

8.1.6.1. Market Revenue and Volume Forecast

Chapter 9. Global Biologics and Biosimilars Market, By Molecule Classification

9.1. Biologics and Biosimilars Market Revenue and Volume, by Molecule Classification

9.1.1. Originator biologics 

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Biosimilars

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Biologics and Biosimilars Market, By Therapy Area 

10.1. Biologics and Biosimilars Market Revenue and Volume, by Therapy Area

10.1.1. Oncology 

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Autoimmune and inflammatory diseases 

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Metabolic and endocrine disorders 

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Infectious diseases 

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Rare diseases 

10.1.5.1. Market Revenue and Volume Forecast

10.1.6. Other therapy areas

10.1.6.1. Market Revenue and Volume Forecast

Chapter 11. Global Biologics and Biosimilars Market, By Route of Administration

11.1. Biologics and Biosimilars Market Revenue and Volume, by Route of Administration

11.1.1. Intravenous 

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Subcutaneous 

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Intramuscular 

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Other routes

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Biologics and Biosimilars Market, By Production Expression System

12.1. Biologics and Biosimilars Market Revenue and Volume, by Production Expression System

12.1.1. Mammalian cell expression 

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Microbial expression 

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Plant and transgenic expression 

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Other expression systems 

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Biologics and Biosimilars Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Product Category

13.1.2. Market Revenue and Volume Forecast, by Molecule Classification

13.1.3. Market Revenue and Volume Forecast, by Therapy Area

13.1.4. Market Revenue and Volume Forecast, by Route of Administration

13.1.5. Market Revenue and Volume Forecast, by Production Expression System

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Product Category

13.1.6.2. Market Revenue and Volume Forecast, by Molecule Classification

13.1.6.3. Market Revenue and Volume Forecast, by Therapy Area

13.1.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.1.6.5. Market Revenue and Volume Forecast, by Production Expression System  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Product Category

13.1.7.2. Market Revenue and Volume Forecast, by Molecule Classification

13.1.7.3. Market Revenue and Volume Forecast, by Therapy Area

13.1.7.4. Market Revenue and Volume Forecast, by Route of Administration

13.1.7.5. Market Revenue and Volume Forecast, by Production Expression System

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Product Category

13.2.2. Market Revenue and Volume Forecast, by Molecule Classification

13.2.3. Market Revenue and Volume Forecast, by Therapy Area

13.2.4. Market Revenue and Volume Forecast, by Route of Administration  

13.2.5. Market Revenue and Volume Forecast, by Production Expression System  

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Product Category

13.2.6.2. Market Revenue and Volume Forecast, by Molecule Classification

13.2.6.3. Market Revenue and Volume Forecast, by Therapy Area

13.2.7. Market Revenue and Volume Forecast, by Route of Administration  

13.2.8. Market Revenue and Volume Forecast, by Production Expression System  

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Product Category

13.2.9.2. Market Revenue and Volume Forecast, by Molecule Classification

13.2.9.3. Market Revenue and Volume Forecast, by Therapy Area

13.2.10. Market Revenue and Volume Forecast, by Route of Administration

13.2.11. Market Revenue and Volume Forecast, by Production Expression System

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Product Category

13.2.12.2. Market Revenue and Volume Forecast, by Molecule Classification

13.2.12.3. Market Revenue and Volume Forecast, by Therapy Area

13.2.12.4. Market Revenue and Volume Forecast, by Route of Administration

13.2.13. Market Revenue and Volume Forecast, by Production Expression System

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Product Category

13.2.14.2. Market Revenue and Volume Forecast, by Molecule Classification

13.2.14.3. Market Revenue and Volume Forecast, by Therapy Area

13.2.14.4. Market Revenue and Volume Forecast, by Route of Administration

13.2.15. Market Revenue and Volume Forecast, by Production Expression System

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Product Category

13.3.2. Market Revenue and Volume Forecast, by Molecule Classification

13.3.3. Market Revenue and Volume Forecast, by Therapy Area

13.3.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.5. Market Revenue and Volume Forecast, by Production Expression System

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Product Category

13.3.6.2. Market Revenue and Volume Forecast, by Molecule Classification

13.3.6.3. Market Revenue and Volume Forecast, by Therapy Area

13.3.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.7. Market Revenue and Volume Forecast, by Production Expression System

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Product Category

13.3.8.2. Market Revenue and Volume Forecast, by Molecule Classification

13.3.8.3. Market Revenue and Volume Forecast, by Therapy Area

13.3.8.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.9. Market Revenue and Volume Forecast, by Production Expression System

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Product Category

13.3.10.2. Market Revenue and Volume Forecast, by Molecule Classification

13.3.10.3. Market Revenue and Volume Forecast, by Therapy Area

13.3.10.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.10.5. Market Revenue and Volume Forecast, by Production Expression System

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Product Category

13.3.11.2. Market Revenue and Volume Forecast, by Molecule Classification

13.3.11.3. Market Revenue and Volume Forecast, by Therapy Area

13.3.11.4. Market Revenue and Volume Forecast, by Route of Administration

13.3.11.5. Market Revenue and Volume Forecast, by Production Expression System

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Product Category

13.4.2. Market Revenue and Volume Forecast, by Molecule Classification

13.4.3. Market Revenue and Volume Forecast, by Therapy Area

13.4.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.5. Market Revenue and Volume Forecast, by Production Expression System

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Product Category

13.4.6.2. Market Revenue and Volume Forecast, by Molecule Classification

13.4.6.3. Market Revenue and Volume Forecast, by Therapy Area

13.4.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.7. Market Revenue and Volume Forecast, by Production Expression System

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Product Category

13.4.8.2. Market Revenue and Volume Forecast, by Molecule Classification

13.4.8.3. Market Revenue and Volume Forecast, by Therapy Area

13.4.8.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.9. Market Revenue and Volume Forecast, by Production Expression System

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Product Category

13.4.10.2. Market Revenue and Volume Forecast, by Molecule Classification

13.4.10.3. Market Revenue and Volume Forecast, by Therapy Area

13.4.10.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.10.5. Market Revenue and Volume Forecast, by Production Expression System

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Product Category

13.4.11.2. Market Revenue and Volume Forecast, by Molecule Classification

13.4.11.3. Market Revenue and Volume Forecast, by Therapy Area

13.4.11.4. Market Revenue and Volume Forecast, by Route of Administration

13.4.11.5. Market Revenue and Volume Forecast, by Production Expression System

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Product Category

13.5.2. Market Revenue and Volume Forecast, by Molecule Classification

13.5.3. Market Revenue and Volume Forecast, by Therapy Area

13.5.4. Market Revenue and Volume Forecast, by Route of Administration

13.5.5. Market Revenue and Volume Forecast, by Production Expression System

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Product Category

13.5.6.2. Market Revenue and Volume Forecast, by Molecule Classification

13.5.6.3. Market Revenue and Volume Forecast, by Therapy Area

13.5.6.4. Market Revenue and Volume Forecast, by Route of Administration

13.5.7. Market Revenue and Volume Forecast, by Production Expression System

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Product Category

13.5.8.2. Market Revenue and Volume Forecast, by Molecule Classification

13.5.8.3. Market Revenue and Volume Forecast, by Therapy Area

13.5.8.4. Market Revenue and Volume Forecast, by Route of Administration

13.5.8.5. Market Revenue and Volume Forecast, by Production Expression System

Chapter 14. Company Profiles

14.1. Samsung Bioepis 

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Sandoz 

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Eli Lilly 

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Bristol Myers Squibb 

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. AstraZeneca 

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Amgen 

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. AbbVie 

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Merck and Co. 

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Johnson and Johnson 

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Roche 

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms